Weekly Snapshots

Current Weekly Snapshot

May 17, 2025

Key highlights from the current weekly snapshot for Johnson & Johnson:

FDA granted priority review for DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed AL amyloidosis
EMA accepted submission for TREMFYA (guselkumab) for the treatment of active psoriatic arthritis
Health Canada approved expanded indication for ERLEADA (apalutamide) for metastatic castration-sensitive prostate cancer

Phase 3 ENSEMBLE trial for COVID-19 vaccine candidate JNJ-78436735 completed enrollment with 45,000 participants
Positive Phase 3 results for TREMFYA (guselkumab) in patients with active psoriatic arthritis showed significant improvement in joint symptoms
New Phase 2 trial initiated for JNJ-63723283 (cetrelimab) in combination with DARZALEX for multiple myeloma

DARZALEX continues to gain market share in multiple myeloma treatment, with 15% year-over-year growth
TREMFYA facing increased competition in psoriasis market from new IL-23 inhibitors
SPRAVATO adoption increasing following expanded reimbursement coverage

New data for DARZALEX FASPRO presented at ASCO 2025 showing improved patient-reported outcomes
Publication in NEJM of long-term safety and efficacy data for TREMFYA in psoriasis
Upcoming presentation at EULAR 2025 on TREMFYA in psoriatic arthritis

Filter by:

Key highlights: DARZALEX FASPRO data at ASCO, TREMFYA market share updates, new clinical trial initiations.

Key highlights: Q1 2025 financial results, SPRAVATO reimbursement expansion, COVID-19 vaccine manufacturing updates.

Key highlights: ERLEADA approval in Canada, new clinical trial data for TREMFYA, competitive landscape updates.

Key highlights: DARZALEX FASPRO FDA submission, ASCO 2025 abstract announcements, market access updates.

Showing 1 to 4 of 24 snapshots